Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06055816
PHASE2
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Sponsor: Zhejiang Cancer Hospital
View on ClinicalTrials.gov
Summary
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2023-09-28
Completion Date
2028-06-30
Last Updated
2023-09-28
Healthy Volunteers
No
Conditions
Interventions
DRUG
Endostar and Envafolimab
Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
Locations (1)
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China